A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.
Adolescent
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Graves Ophthalmopathy
/ diagnosis
Health Services Accessibility
Humans
Male
Middle Aged
Models, Statistical
Patient Care Team
/ standards
Prognosis
Quality of Life
Referral and Consultation
/ standards
Retrospective Studies
Surveys and Questionnaires
Young Adult
Graves disease
Graves ophthalmopathy
Graves orbitopathy
optic neuropathy
thyroid eye disease
thyroid-associated ophthalmopathy
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
02
2021
accepted:
16
04
2021
entrez:
24
5
2021
pubmed:
25
5
2021
medline:
21
12
2021
Statut:
epublish
Résumé
There is no universal consensus on the practical implementation and evaluation of the Amsterdam Declaration on Graves Orbitopathy in a Multidisciplinary Thyroid Eye Disease (MDTED) pathway. Recent recommendations from the UK TEAMeD-5 and BOPSS initiative highlight the importance of prevention, screening, and prompt referral of patients with moderate to severe and sight-threatening thyroid eye disease to multidisciplinary (MDTED) clinics and recommends annual auditing. We propose a practical service evaluation model with Key Performance Indicators (KPI) that are achievable and could be implemented across most TED pathways. We conducted a service evaluation from an integrated TED pathway in London with three MDTED clinics. Data was collected retrospectively from consecutive TED patients included: 1) Patient demographics, 2) Referral to first appointment time, 3) Documented smoking cessation and selenium supplementation advice, 4) Presenting disease activity and severity, 5) Investigations and treatments, including radio-iodine, 6) Time from decision to treatment initiation, 7) Initial and subsequent thyroid status. The median age was 49.0 yrs, 77.5% (183/236) were female and 49.5% (101/204) Afro-Caribbean or Asian. At their first clinic attendance, 47.6% (110/231) were biochemically euthyroid and 76.7% (79/103) at discharge. All 23.1% (52/225) current smokers received smoking cessation advice and 64.8% (153/236) received selenium supplementation advice. Intravenous methylprednisolone was given to 33.9% (80/236) patients and 12.7% (30/236) received second-line immunosuppression. All 7.2% (17/236) patients with sight-threatening disease received treatment within two weeks of diagnosis. This study forms a waymark for other units using TEAMeD-5 and BOPSS audit criteria. Dedicated electronic patient records with ongoing data capture, including quality of life assessments, and diagnostic coding would significantly aid future auditing, improve patient care, and facilitate a national audit of TED management. A future survey when the TED standards have become embedded would be instructive to see whether this has improved TED care.
Sections du résumé
Background/Aims
There is no universal consensus on the practical implementation and evaluation of the Amsterdam Declaration on Graves Orbitopathy in a Multidisciplinary Thyroid Eye Disease (MDTED) pathway. Recent recommendations from the UK TEAMeD-5 and BOPSS initiative highlight the importance of prevention, screening, and prompt referral of patients with moderate to severe and sight-threatening thyroid eye disease to multidisciplinary (MDTED) clinics and recommends annual auditing. We propose a practical service evaluation model with Key Performance Indicators (KPI) that are achievable and could be implemented across most TED pathways.
Material and Methods
We conducted a service evaluation from an integrated TED pathway in London with three MDTED clinics. Data was collected retrospectively from consecutive TED patients included: 1) Patient demographics, 2) Referral to first appointment time, 3) Documented smoking cessation and selenium supplementation advice, 4) Presenting disease activity and severity, 5) Investigations and treatments, including radio-iodine, 6) Time from decision to treatment initiation, 7) Initial and subsequent thyroid status.
Results
The median age was 49.0 yrs, 77.5% (183/236) were female and 49.5% (101/204) Afro-Caribbean or Asian. At their first clinic attendance, 47.6% (110/231) were biochemically euthyroid and 76.7% (79/103) at discharge. All 23.1% (52/225) current smokers received smoking cessation advice and 64.8% (153/236) received selenium supplementation advice. Intravenous methylprednisolone was given to 33.9% (80/236) patients and 12.7% (30/236) received second-line immunosuppression. All 7.2% (17/236) patients with sight-threatening disease received treatment within two weeks of diagnosis.
Conclusions
This study forms a waymark for other units using TEAMeD-5 and BOPSS audit criteria. Dedicated electronic patient records with ongoing data capture, including quality of life assessments, and diagnostic coding would significantly aid future auditing, improve patient care, and facilitate a national audit of TED management. A future survey when the TED standards have become embedded would be instructive to see whether this has improved TED care.
Identifiants
pubmed: 34025584
doi: 10.3389/fendo.2021.669871
pmc: PMC8138583
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
669871Informations de copyright
Copyright © 2021 Farag, Feeney, Lee, Nagendran, Jain, Aziz, Akishar, Bravis and Meeran.
Déclaration de conflit d'intérêts
VL is the British Oculoplastic Surgery Society National Lead for TEAMeD (UK Thyroid Eye Disease Amsterdam Declaration Implementation Group). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Orbit. 2017 Jun;36(3):159-169
pubmed: 28296512
Eur J Endocrinol. 2011 May;164(5):649-55
pubmed: 21367964
Orbit. 2018 Oct;37(5):325-330
pubmed: 29319381
AJNR Am J Neuroradiol. 2020 Aug;41(8):1466-1472
pubmed: 32796099
Br J Ophthalmol. 2015 Nov;99(11):1531-5
pubmed: 25953846
Br J Ophthalmol. 1998 Jul;82(7):773-9
pubmed: 9924370
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
Clin Endocrinol (Oxf). 2008 Dec;69(6):943-50
pubmed: 18429949
Eye (Lond). 2020 Sep;34(9):1662-1671
pubmed: 31836832
J Clin Pharm Ther. 2000 Jun;25(3):227-34
pubmed: 10886467
J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9
pubmed: 23408569
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):273-9
pubmed: 22632364
Thyroid. 2014 Sep;24(9):1407-18
pubmed: 24967886
Orphanet J Rare Dis. 2017 Apr 20;12(1):72
pubmed: 28427469
Int Ophthalmol. 2014 Feb;34(1):1-6
pubmed: 23549634
Intern Med. 2014;53(5):353-60
pubmed: 24583420
J Clin Endocrinol Metab. 2012 Jul;97(7):2325-32
pubmed: 22518849